Marcie A. Goldstein
Lawyers
Represents broker-dealers and issuers on securities law compliance and FINRA requirements.
Marcie represents broker-dealers and issuers in connection with public and private securities offerings, mergers and other corporate transactions with respect to compliance with state securities laws and FINRA requirements.
Experience highlights
Recent Representations
- Alight $178 million debut secondary offering
- Akoya Biosciences $50 million at-the-market program
- Prime Medicine $175 million IPO
- Gamida Cell $20 million follow-on offering
- Alignment Healthcare $132.75 million secondary offering
- Bloom Energy $388.7 million follow-on offering
- Oak Street Health $180.3 million secondary offering
- Terns Pharmaceuticals $65 million common stock and pre-funded warrants offering
- Arrival $300 million at-the-market offering
- TransMedics Group $150 million follow-on offering
- RxSight $50 million at-the-market offering
- Legend Biotech $403 million follow-on offering
- Revolution Medicines $264.5 million follow-on offering
- ChargePoint Holdings $500 million at-the-market offering
- Hennessy Capital Investment VI $300 million IPO
- Gracell Biotechnologies at-the-market offering
Insights
Education
J.D., Wayne State University Law School
B.A., University of Michigan
- with honors
Professional history
- Counsel, 1988-present
- Associate, Davis Polk, 1983-1988
- Examiner, Michigan Corporation & Securities Bureau, 1980-1981
- Assistant Director, Corporate Financing, National Association of Securities Dealers, 1982-1983
Qualifications and admissions
- State of New York